Newsletter Archives - Page 4 of 4 - Hamlet BioPharma

Newsletter

Nov

10

2025

PRESS RELEASE – Lund, November 10th, 2025 – Hamlet BioPharma Receives FDA Pivotal-Study Feedback for Novel Neoadjuvant Therapy in Non–Muscle Invasive Bladder Cancer

Hamlet Biopharma

|

Newsletter, Press releases

HAMLET BioPharma, a clinical‑stage biopharmaceutical company advancing targeted oncological and other therapies, today announced it has received writt...

Read more

Nov

05

2025

Newsletter – Clinical study in infants with febrile kidney infection supports Hamlet BioPharma’s strategy for non-antibiotic treatment of bacterial infections

Hamlet Biopharma

|

One of the most comprehensive studies ever conducted in childhood urinary tract infection shows that a chaotic immune response causes symptoms and dam...

Read more

Nov

05

2025

Nyhetsbrev – Klinisk studie på spädbarn bekräftar Hamlet BioPharmas strategi för icke-antibiotisk behandling av infektioner

Hamlet Biopharma

|

En av de mest omfattande studierna någonsin av urinvägsinfektion hos barn visar att ett kaotisk immunsvar orsakar symptom och vävnadsskada – int...

Read more

Dec

07

2023

Newsletter – Continuing development of brain tumor therapy

Hamlet Biopharma

|

The brain and spinal cord form the central nervous system, where vital functions are controlled. Brain tumors that disturb those functions may be...

Read more

Nov

02

2023

Newsletter – Bladder cancer

Hamlet Biopharma

|

...

Read more

Oct

16

2023

Newsletter – Strong anti-tumor effects detected in Alpha1H patients

Hamlet Biopharma

|

...

Read more

Oct

03

2023

Newsletter – FDA approval

Hamlet Biopharma

|

...

Read more

1
2
3
4

Recent posts

Pressrelease – Lund, June 25th, 2026 – Hamlet BioPharma secures drug manufacturing at Phase III quality and release of Alpha1H for distribution to clinical trial sites

June 25, 2026

Pressrelease – Lund, June 23rd, 2026 – Hamlet BioPharma’s monthly digital investors’ meeting on June 30th

June 23, 2026

Press release – Lund, June 22th, 2026 – Clinical trial expansion in the US, in collaboration with the University of Iowa, to treat high-risk, resistant, non-muscle-invasive bladder cancer (NMIBC)

June 22, 2026

Press release – Lund, June 17th, 2026 – Pre-initiation visit in Prague, for the Phase III trial of Alpha1H in bladder cancer

June 17, 2026

An innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections.

Hamlet BioPharma AB
Klinikgatan 32
SE-222 42 Lund
info@hamletbiopharma.com
Org. no. 556568-8958

Subscribe to receive
Pressreleases and Newsletters

© 2026

Hamlet BioPharma.